Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bronchodilator Effects of QVM149 in Asthma
NCT03108027Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2017
- Primary completion
- Feb 2018
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in asthma (6 arms), sponsored by Novartis. Primary endpoint: FEV1 Standardized Area Under the Curve (AUC 0-24h) at Day 14. Started Jun 2017; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03108027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108027.